STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 7, 2010, Pages 654-664

  Armanious, Hanan ^a   Gelebart, Pascal ^a   Mackey, John ^a   Ma, Yupo ^b   Lai, Raymond ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

catenin; Breast cancer; BT 474; MCF 7; STAT3

Indexed keywords

BETA CATENIN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CHROMATIN IMMUNOPRECIPITATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PROMOTER REGION; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

BETA CATENIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; PROMOTER REGIONS, GENETIC; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 77956082214     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Huber AH, Weis WI. The structure of the betacatenin/E-cadherin complex and the molecular basis of diverse ligand recognition by betacatenin. Cell. 2001 May 4;105(3):391-402.
2. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):119-31.
3. Polakis P. Wnt signaling and cancer. Genes Dev. 2000 Aug 1;14(15):1837-51.
4. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006 Nov 3;127 (3):469-80.
5. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006 Aug 11;281(32):22429-33.
6. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science. 1998 Sep 4;281 (5382):1509-12.
7. Mikels AJ, Nusse R. Wnts as ligands: processing, secretion and reception. Oncogene. 2006 Dec 4;25(57):7461-8.
8. Miller JR. The Wnts. Genome Biol. 2002;3 (1):REVIEWS3001.
9. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7.
10. Ewan KB, Dale TC. The potential for targeting oncogenic WNT/beta-catenin signaling in therapy. Curr Drug Targets. 2008 Jul;9(7):532-47.
11. Imbert A, Eelkema R, Jordan S, Feiner H, Cowin P. Delta N89 beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol. 2001 Apr 30;153 (3):555-68.
12. Asgarian N, Hu X, Aktary Z, Chapman KA, Lam L, Chibbar R, Mackey J, Greiner R, Pasdar M. Learning to predict relapse in invasive ductal carcinomas based on the subcellular localization of junctional proteins. Breast Cancer Res Treat. 2009 Sep 29.
13. Lim SC, Lee MS. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep. 2002 Sep-Oct;9(5):915-28.
14. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6.
15. Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep. 2006 Mar;15(3):701-7.
16. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 2007;9(5):R63.
17. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol. 2001 Sep;3(9):793 -801.
18. Levina E, Oren M, Ben-Ze'ev A. Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics. Oncogene. 2004 May 27;23 (25):4444-53.
19. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell. 2001 May;7(5):927-36.
20. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets. 2004 Oct;8(5):409-22.
21. Kunigal S, Lakka SS, Sodadasu PK, Estes N, Rao JS. Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int J Oncol. 2009 May;34(5):1209-20.
22. Dien J, Amin HM, Chiu N, Wong W, Frantz C, Chiu B, Mackey JR, Lai R. Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol. 2006 Aug;169(2):633-42.
23. Kawada M, Seno H, Uenoyama Y, Sawabu T, Kanda N, Fukui H, Shimahara Y, Chiba T. Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer. Cancer Res. 2006 Mar 15;66(6):2913-7.
24. Staal FJ, Noort Mv M, Strous GJ, Clevers HC. Wnt signals are transmitted through Nterminally dephosphorylated beta-catenin. EMBO Rep. 2002 Jan;3(1):63-8.
25. Sekikawa A, Fukui H, Fujii S, Ichikawa K, Tomita S, Imura J, Chiba T, Fujimori T. REG Ialpha protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells. Carcinogenesis. 2008 Jan;29(1):76-83.
26. Seidel HM, Milocco LH, Lamb P, Darnell JE, Jr., Stein RB, Rosen J. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3041-5.
27. Ehret GB, Reichenbach P, Schindler U, Horvath CM, Fritz S, Nabholz M, Bucher P. DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem. 2001 Mar 2;276(9):6675-88.
28. Bard JD, Gelebart P, Amin HM, Young LC, Ma Y, Lai R. Signal transducer and activator of transcription 3 is a transcriptional factor regulating the gene expression of SALL4. FASEB J. 2009 May;23(5):1405-14.
29. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T, Hayward SW, Bhowmick NA. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene. 2008 Nov 27;27 (56):7118-30.
30. Fujio Y, Matsuda T, Oshima Y, Maeda M, Mohri T, Ito T, Takatani T, Hirata M, Nakaoka Y, Kimura R, Kishimoto T, Azuma J. Signals through gp130 upregulate Wnt5a and contribute to cell adhesion in cardiac myocytes. FEBS Lett. 2004 Aug 27;573(1-3):202-6.
31. Miyagi C, Yamashita S, Ohba Y, Yoshizaki H, Matsuda M, Hirano T. STAT3 noncellautonomously controls planar cell polarity during zebrafish convergence and extension. J Cell Biol. 2004 Sep 27;166(7):975-81.
32. Pu P, Zhang Z, Kang C, Jiang R, Jia Z, Wang G, Jiang H. Downregulation of Wnt2 and betacatenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. 2009 Apr;16 (4):351-61.
33. Wang JS, Zheng CL, Wang YJ, Wen JF, Ren HZ, Liu Y, Jiang HY. Gene silencing of beta-catenin by RNAi inhibits cell proliferation in human esophageal cancer cells in vitro and in nude mice. Dis Esophagus. 2009;22(2):151-62.
34. Huang WS, Wang JP, Wang T, Fang JY, Lan P, Ma JP. ShRNA-mediated gene silencing of betacatenin inhibits growth of human colon cancer cells. World J Gastroenterol. 2007 Dec 28;13 (48):6581-7.
35. Simpson KJ, Selfors LM, Bui J, Reynolds A, Leake D, Khvorova A, Brugge JS. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol. 2008 Sep;10(9):1027-38.
36. Yan S, Zhou C, Zhang W, Zhang G, Zhao X, Yang S, Wang Y, Lu N, Zhu H, Xu N. beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett. 2008 Nov 18;271(1):85-97.
37. Takemaru KI, Ohmitsu M, Li FQ. An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics. Handb Exp Pharmacol. 2008(186):261-84.
38. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs. 2009 Jan;18(1):45-56.